CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) Director Andrew Schwab sold 400,000 shares of the firm's stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the completion of the sale, the director directly owned 2,033,270 shares of the company's stock, valued at approximately $8,214,410.80. This represents a 16.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
CAMP4 Therapeutics Stock Performance
NASDAQ:CAMP opened at $3.96 on Tuesday. The stock's fifty day moving average price is $4.13 and its two-hundred day moving average price is $4.35. CAMP4 Therapeutics Corporation has a 52-week low of $1.41 and a 52-week high of $7.75. The company has a market cap of $248.49 million, a price-to-earnings ratio of -1.71 and a beta of 0.22.
CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last released its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.34). The firm had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. On average, equities analysts predict that CAMP4 Therapeutics Corporation will post -0.57 EPS for the current fiscal year.
Analyst Ratings Changes
Several brokerages have weighed in on CAMP. Zacks Research raised CAMP4 Therapeutics from a "strong sell" rating to a "hold" rating in a report on Monday, August 17th. Weiss Ratings raised shares of CAMP4 Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, August 14th. Chardan Capital set a $6.50 price target on shares of CAMP4 Therapeutics and gave the stock a "buy" rating in a research report on Wednesday, June 10th. JPMorgan Chase & Co. raised shares of CAMP4 Therapeutics from a "neutral" rating to an "overweight" rating and boosted their price target for the stock from $5.00 to $9.00 in a research note on Tuesday, June 16th. Finally, Piper Sandler restated an "overweight" rating and issued a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $9.56.
View Our Latest Report on CAMP4 Therapeutics
Hedge Funds Weigh In On CAMP4 Therapeutics
Several hedge funds have recently added to or reduced their stakes in the stock. Jupiter Topco LLC bought a new position in CAMP4 Therapeutics during the second quarter worth about $27,581,000. Janus Henderson Group PLC raised its position in shares of CAMP4 Therapeutics by 35.9% in the 4th quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider's stock valued at $38,807,000 after acquiring an additional 1,666,666 shares during the period. 5AM Venture Management LLC acquired a new stake in shares of CAMP4 Therapeutics in the 2nd quarter valued at approximately $25,647,928. Vivo Capital LLC boosted its stake in CAMP4 Therapeutics by 8.3% during the 4th quarter. Vivo Capital LLC now owns 4,246,568 shares of the Wireless communications provider's stock worth $26,031,000 after acquiring an additional 325,000 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in CAMP4 Therapeutics during the 4th quarter worth approximately $14,938,000.
CAMP4 Therapeutics Company Profile
(
Get Free Report)
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
